EE03965B1 - Maatriksi metalloproteinaasi bifenüülsulfoonamiidinhibiitorid - Google Patents

Maatriksi metalloproteinaasi bifenüülsulfoonamiidinhibiitorid

Info

Publication number
EE03965B1
EE03965B1 EE9800397A EE9800397A EE03965B1 EE 03965 B1 EE03965 B1 EE 03965B1 EE 9800397 A EE9800397 A EE 9800397A EE 9800397 A EE9800397 A EE 9800397A EE 03965 B1 EE03965 B1 EE 03965B1
Authority
EE
Estonia
Prior art keywords
matrix metalloproteinase
biphenylsulfonamide
inhibitors
alkyl
nhoh
Prior art date
Application number
EE9800397A
Other languages
English (en)
Estonian (et)
Other versions
EE9800397A (et
Inventor
Michael O'brien Patrick
Robert Sliskovic Drago
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of EE9800397A publication Critical patent/EE9800397A/xx
Publication of EE03965B1 publication Critical patent/EE03965B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/42Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
EE9800397A 1996-05-17 1997-04-24 Maatriksi metalloproteinaasi bifenüülsulfoonamiidinhibiitorid EE03965B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1746096P 1996-05-17 1996-05-17
PCT/US1997/006801 WO1997044315A1 (en) 1996-05-17 1997-04-24 Biphenylsulfonamide matrix metalloproteinase inhibitors

Publications (2)

Publication Number Publication Date
EE9800397A EE9800397A (et) 1999-06-15
EE03965B1 true EE03965B1 (et) 2003-02-17

Family

ID=21782716

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800397A EE03965B1 (et) 1996-05-17 1997-04-24 Maatriksi metalloproteinaasi bifenüülsulfoonamiidinhibiitorid

Country Status (23)

Country Link
EP (1) EP0901466B1 (xx)
JP (1) JP2000511175A (xx)
KR (1) KR20000011095A (xx)
CN (1) CN1077885C (xx)
AT (1) ATE207891T1 (xx)
BG (1) BG63940B1 (xx)
BR (1) BR9710841A (xx)
CA (1) CA2253342A1 (xx)
CZ (1) CZ294063B6 (xx)
DE (1) DE69707865T2 (xx)
DK (1) DK0901466T3 (xx)
EA (1) EA001561B1 (xx)
EE (1) EE03965B1 (xx)
ES (1) ES2167733T3 (xx)
HK (1) HK1019585A1 (xx)
IL (1) IL126832A0 (xx)
NO (1) NO312510B1 (xx)
NZ (1) NZ332711A (xx)
PL (1) PL186416B1 (xx)
PT (1) PT901466E (xx)
SK (1) SK282863B6 (xx)
WO (1) WO1997044315A1 (xx)
ZA (1) ZA974223B (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022898A (en) * 1994-06-22 2000-02-08 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US6124333A (en) * 1995-06-22 2000-09-26 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
NZ334897A (en) * 1996-12-09 2001-02-23 Warner Lambert Co Medicaments for treating and preventing heart failure and ventricular dilatation
ES2212142T3 (es) 1996-12-17 2004-07-16 Warner-Lambert Company Llc Uso de inhibidores de metaloproteinasas de la matriz para promover la curacion de heridas.
SI0946166T1 (en) * 1996-12-17 2004-06-30 Warner-Lambert Company Llc Use of matrix metalloproteinase inhibitors for promoting wound healing
GB9706255D0 (en) * 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
WO1999004780A1 (fr) 1997-07-22 1999-02-04 Shionogi & Co., Ltd. Agent therapeutique ou prophylactique de traitement de la glomerulopathie
KR20010033473A (ko) * 1997-12-23 2001-04-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ace 저해제-mmp 저해제의 병용 제제
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
SK11692000A3 (sk) 1998-02-04 2001-02-12 Novartis Ag Sulfonylaminoderiváty, ktoré inhibujú metaloproteinázy degradujúce matricu, spôsob ich prípravy a farmaceutická kompozícia, ktorá ich obsahuje
KR20010041916A (ko) * 1998-03-17 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 스타틴-매트릭스 메탈로프로테이나제 저해제 복합제제
EP0967201A1 (en) * 1998-05-20 1999-12-29 Roche Diagnostics GmbH Pharmaceutical agents containing sulfonamids as matrix metalloproteinase inhibitors
DK1097159T3 (da) 1998-07-16 2003-03-10 Aventis Pharma Gmbh Phosphin- og phosphonsyrederivater som lægemidler
JP2002521328A (ja) * 1998-07-21 2002-07-16 ワーナー−ランバート・カンパニー アテローム性動脈硬化症病変の治療のためのacat阻害剤およびmmp阻害剤の併用投与
DE19851184A1 (de) 1998-11-06 2000-05-11 Aventis Pharma Gmbh N-Arylsulfonyl-aminosäure-omega-amide
PL351374A1 (en) * 1999-04-19 2003-04-07 Shionogi & Co Sulfonamide derivatives having oxadiazole rings
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
KR100733752B1 (ko) 1999-11-26 2007-06-29 시오노기세이야쿠가부시키가이샤 Npyy5 길항제
EP1331224A4 (en) * 2000-09-29 2004-03-17 Shionogi & Co THIAZOLE AND OXAZOLE DERIVATIVES
GB0103303D0 (en) 2001-02-09 2001-03-28 Novartis Ag Organic compounds
MXPA01013326A (es) * 2001-02-14 2002-08-26 Warner Lambert Co Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
JP4219810B2 (ja) * 2001-10-26 2009-02-04 塩野義製薬株式会社 Mmp阻害作用を有するスルホンアミド誘導体
GB0314488D0 (en) * 2003-06-20 2003-07-23 Glaxo Group Ltd Therapeutically useful compounds
AU2003304638A1 (en) 2003-12-04 2005-07-14 Wyeth Biaryl sulfonamides and methods for using same
JP2007530546A (ja) * 2004-03-22 2007-11-01 サザン リサーチ インスティチュート マトリックスメタロプロテイナーゼの非ペプチドインヒビター
CN101279956B (zh) * 2008-04-25 2011-06-15 南昌大学 一种基质金属蛋白酶抑制剂及合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US6022898A (en) * 1994-06-22 2000-02-08 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors

Also Published As

Publication number Publication date
IL126832A0 (en) 1999-08-17
JP2000511175A (ja) 2000-08-29
ES2167733T3 (es) 2002-05-16
DK0901466T3 (da) 2002-02-18
DE69707865D1 (de) 2001-12-06
CZ294063B6 (cs) 2004-09-15
NO312510B1 (no) 2002-05-21
KR20000011095A (ko) 2000-02-25
AU713286B2 (en) 1999-11-25
CN1077885C (zh) 2002-01-16
NO985326L (no) 1999-01-14
BG102918A (en) 1999-09-30
EA199800988A1 (ru) 1999-04-29
EP0901466B1 (en) 2001-10-31
CZ366898A3 (cs) 1999-02-17
CA2253342A1 (en) 1997-11-27
CN1219166A (zh) 1999-06-09
NZ332711A (en) 2000-06-23
DE69707865T2 (de) 2002-05-02
NO985326D0 (no) 1998-11-16
BG63940B1 (bg) 2003-07-31
PL329929A1 (en) 1999-04-26
HK1019585A1 (en) 2000-02-18
ZA974223B (en) 1997-12-10
EA001561B1 (ru) 2001-04-23
SK157798A3 (en) 1999-04-13
EE9800397A (et) 1999-06-15
PT901466E (pt) 2002-04-29
WO1997044315A1 (en) 1997-11-27
PL186416B1 (pl) 2004-01-30
BR9710841A (pt) 1999-08-17
AU2680397A (en) 1997-12-09
SK282863B6 (sk) 2002-12-03
EP0901466A1 (en) 1999-03-17
ATE207891T1 (de) 2001-11-15

Similar Documents

Publication Publication Date Title
DK0901466T3 (da) Biphenylsulfonamid-matriksmetalloproteinase-inhibitorer
RU2221781C2 (ru) Тиолсульфоновые соединения в качестве ингибитора матриксной металлопротеазы и способы лечения
AU6894800A (en) Caspase inhibitors and uses thereof
GB9801690D0 (en) Therapeutic agents
UY25322A1 (es) Compuestos de tiourea y benzamida,composiciones y metodos para tratar y prevenir enfermedades inflamatorias y aterosclerosis
WO2003024448A3 (en) Inhibitors of histone deacetylase
ATE289590T1 (de) Beta-sulfonyl-hydroxamsäuren als matrix- metalloproteinaseinhibitoren
DE69612003D1 (de) Substituierte benzolaktamverbindungen als substanz-p-antagonisten
EA200101085A1 (ru) Гидроксамовые кислоты, производные ароматических сульфонов, - ингибиторы металлопротеаз
EA200100804A1 (ru) Сульфоароматические производные гидроксамовой кислоты как ингибиторы металлопротеаз
DK0946166T3 (da) Anvendelse af matrixmetalloproteinaseinhibitorer til fremme af sårheling
PT1250340E (pt) Metodos e compostos para inibicao de mrp1
NZ333550A (en) Matrix metalloproteinase inhibitors for inhibiting the release of TNF
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
DE69736945D1 (de) Biphenylverbindungen sowie ihre anwendung als östrogene mittel
ATE282602T1 (de) Buttersäure matrix-metalloproteinase-inhibitoren
PL317349A1 (en) Organic compounds
NZ516620A (en) 1,4-substituted 4,4-diaryl cyclohexanes
BR0214886A (pt) Fenilalquinos
ES2173634T3 (es) Compuestos heterociclicos que presentan actividad inhibidora de mmp y tnf.
PT971714E (pt) Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

MM4A Lapsed by not paying the annual fees

Effective date: 20050424